Anika Therapeutics, Inc.

NasdaqGS:ANIK Stock Report

Market Cap: US$207.8m

Anika Therapeutics Management

Management criteria checks 2/4

Anika Therapeutics' CEO is Cheryl Blanchard, appointed in Feb 2020, has a tenure of 5.25 years. total yearly compensation is $5.10M, comprised of 14.6% salary and 85.4% bonuses, including company stock and options. directly owns 1.47% of the company’s shares, worth $3.06M. The average tenure of the management team and the board of directors is 3.3 years and 4.7 years respectively.

Key information

Cheryl Blanchard

Chief executive officer

US$5.1m

Total compensation

CEO salary percentage14.6%
CEO tenure5.3yrs
CEO ownership1.5%
Management average tenure3.3yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

Dec 19
Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet

Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Jan 30
Is There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 44% Undervaluation?

Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Aug 03
Companies Like Anika Therapeutics (NASDAQ:ANIK) Can Afford To Invest In Growth

Anika Therapeutics: New Share Price Low May Imply New Upside Opportunity

Mar 11

Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

Jun 25
Are Investors Undervaluing Anika Therapeutics, Inc. (NASDAQ:ANIK) By 48%?

How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Mar 16
How Much Are Anika Therapeutics, Inc. (NASDAQ:ANIK) Insiders Taking Off The Table?

Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

Feb 09
Anika Therapeutics (NASDAQ:ANIK) Seems To Use Debt Quite Sensibly

An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

Jan 13
An Intrinsic Calculation For Anika Therapeutics, Inc. (NASDAQ:ANIK) Suggests It's 32% Undervalued

If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

Dec 18
If You Had Bought Anika Therapeutics' (NASDAQ:ANIK) Shares A Year Ago You Would Be Down 21%

CEO Compensation Analysis

How has Cheryl Blanchard's remuneration changed compared to Anika Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$5mUS$744k

-US$9m

Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$74m

Mar 31 2024n/an/a

-US$77m

Dec 31 2023US$4mUS$726k

-US$3m

Sep 30 2023n/an/a

-US$25m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$22m

Dec 31 2022US$6mUS$695k

US$2m

Sep 30 2022n/an/a

-US$16m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022n/an/a

-US$2m

Dec 31 2021US$4mUS$668k

US$4m

Sep 30 2021n/an/a

-US$6m

Jun 30 2021n/an/a

-US$13m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$10mUS$548k

-US$24m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

US$11m

Mar 31 2020n/an/a

US$28m

Dec 31 2019US$187kn/a

US$27m

Sep 30 2019n/an/a

US$31m

Jun 30 2019n/an/a

US$29m

Mar 31 2019n/an/a

US$30m

Dec 31 2018US$167kn/a

US$19m

Compensation vs Market: Cheryl's total compensation ($USD5.10M) is above average for companies of similar size in the US market ($USD1.59M).

Compensation vs Earnings: Cheryl's compensation has increased whilst the company is unprofitable.

CEO

Cheryl Blanchard (60 yo)

5.3yrs

Tenure

US$5,103,466

Compensation

Dr. Cheryl Renee Blanchard, Ph. D. is Director of Elute, Inc. from May 2013. She serves as the President & Chief Executive Officer of Anika Therapeutics, Inc. since April 26, 2020. She serves as Director o...

Leadership Team

NamePositionTenureCompensationOwnership
Cheryl Blanchard
President5.3yrsUS$5.10m1.47%
$ 3.1m
Stephen Griffin
Executive VPless than a yearUS$2.85mno data
David Colleran
Executive VP5.2yrsUS$1.67m0.34%
$ 703.0k
Ian McLeod
VP & Chief Accounting Officerno datano data0.11%
$ 235.2k
Mark Namaroff
Vice President of Investor Relationsno datano datano data
James Chase
Senior Vice President of International Sales & Marketing5yrsno datano data
Ben Joseph
Vice President of Commercial & Corporate Development3.3yrsno datano data
Lisa Funiciello
Vice President of Human Resources3.3yrsno datano data
Mira Leiwant
Senior Vice President of Regulatoryless than a yearno datano data

3.3yrs

Average Tenure

56yo

Average Age

Experienced Management: ANIK's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Cheryl Blanchard
President6.8yrsUS$5.10m1.47%
$ 3.1m
William Jellison
Independent Director1yrUS$198.37k0.019%
$ 39.6k
John Henneman
Independent Chair of the Board5.8yrsUS$252.64k0.21%
$ 438.8k
Susan L. Vogt
Independent Director6.6yrsUS$223.99k0.21%
$ 443.9k
Sheryl Conley
Independent Director3.6yrsUS$221.63k0.14%
$ 291.8k
Glenn Larsen
Independent Director10.3yrsUS$212.49k0.21%
$ 444.5k
Joseph Capper
Independent Director1yrUS$196.99kno data
Gary Fischetti
Independent Director2.1yrsUS$215.24k0.092%
$ 192.1k
Stephen Richard
Independent Director4.7yrsUS$248.98k0.20%
$ 409.5k

4.7yrs

Average Tenure

63yo

Average Age

Experienced Board: ANIK's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 12:49
End of Day Share Price 2025/05/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anika Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PetuskyBarrington Research Associates, Inc.
Anderson SchockB. Riley Securities, Inc.
Mark LandyNorthland Capital Markets